Phase Ib/II study of LGX818 and cetuximab or LGX818, BYL719 and cetuximab in BRAF mutant mCRC
Diseases and Conditions Researched
What is the purpose of this trial?
Phase Ib: To estimate the MTD and/or RP2D of LGX818 in combination with cetuximab ± BYL719
Phase II: To compare the efficacy of the dual (LGX818, cetuximab) and triple (LGX818, BYL719, cetuximab) combinations.
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.